<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>51</patient-age><report-id>PHHY2012CA082011</report-id><gender>female</gender><reactions><reaction>TSH levels were elevated at 7.26</reaction><reaction>Panic attack</reaction><reaction>Increased lightheadedness/lightheaded</reaction><reaction>Going to the washroom more often, bladder urgency</reaction><reaction>Nightmare</reaction><reaction>Pressure in her chest</reaction><reaction>Had two 30 seconds episodes of stabbing pain in mid-chest</reaction><reaction>Tired/ Increased fatigue</reaction><reaction>Blood pressure increased (148/98)</reaction><reaction>Headache</reaction><reaction>Generalized weakness</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>GILENYA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>GABAPENTIN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>WELLBUTRIN XL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>VENLAFAXINE XR</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>SYNTHROID</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>MINESTRIN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>COLACE</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Relapsing-remitting multiple sclerosis</indication></indications><outcomes/><country>Canada</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149677_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152623</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>3</safetyreportversion>
		<safetyreportid>PHHY2012CA082011</safetyreportid>
		<primarysourcecountry>CA</primarysourcecountry>
		<occurcountry>CA</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-09-19</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-18</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012CA082011</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle>RN</reportertitle>
			<reportergivename>Nadia</reportergivename>
			<reporterfamilyname>Spinelli</reporterfamilyname>
			<reportercountry>CA</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>CA</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>LG</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19601207</patientbirthdate>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Anxiety</patientepisodename>
				<patientmedicalcomment>Used an unspecified medication for anxiety</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypertension</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>TSH levels were elevated at 7.26</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>TSH increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Blood thyroid stimulating hormone increased</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Panic attack</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Panic attack</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Panic attack</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Increased lightheadedness/lightheaded</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Lightheadedness</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Dizziness</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120918</reactionstartdate>
				<reactionfirsttime>1</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Going to the washroom more often, bladder urgency</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Urinary urgency</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Micturition urgency</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Going to the washroom more often, bladder urgency</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Frequency urinary</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Pollakiuria</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Nightmare</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Nightmare</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Nightmare</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Pressure in her chest</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Chest pressure</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Chest discomfort</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Had two 30 seconds episodes of stabbing pain in mid-chest</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Chest pain</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Chest pain</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Tired/ Increased fatigue</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Fatigue aggravated</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Fatigue</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120919</reactionstartdate>
				<reactionfirsttime>2</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>2</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Blood pressure increased (148/98)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Blood pressure increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Blood pressure increased</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120918</reactionstartdate>
				<reactionfirsttime>1</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Headache</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Headache</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Headache</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120919</reactionstartdate>
				<reactionfirsttime>2</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>2</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Generalized weakness</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Weakness generalized</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Asthenia</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120918</testdate>
				<testname>Blood pressure</testname>
				<lowtestrange>120/80</lowtestrange>
				<hightestrange>Normal</hightestrange>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120918</testdate>
				<testname>Blood pressure</testname>
				<lowtestrange>120/80</lowtestrange>
				<hightestrange>Normal</hightestrange>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120918</testdate>
				<testname>Blood pressure</testname>
				<lowtestrange>120/80</lowtestrange>
				<hightestrange>Normal</hightestrange>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120918</testdate>
				<testname>Blood pressure</testname>
				<lowtestrange>120/80</lowtestrange>
				<hightestrange>Normal</hightestrange>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120918</testdate>
				<testname>Blood pressure</testname>
				<lowtestrange>120/80</lowtestrange>
				<hightestrange>Normal</hightestrange>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>GILENYA</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugbatchnumb>S0008</drugbatchnumb>
				<drugauthorizationnumb>22-527</drugauthorizationnumb>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>.5</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>0.5 mg, QD</drugdosagetext>
				<drugdosageform normalized="capsule">Capsule</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Relapsing-remitting multiple sclerosis</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-09-18</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugadditional code="ExpDT=??-FEB-2013"/>
				<activesubstance>
					<activesubstancename>FINGOLIMOD</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Asthenia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Asthenia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood pressure increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood pressure increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood thyroid stimulating hormone increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood thyroid stimulating hormone increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Chest discomfort</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Chest discomfort</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Chest pain</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Chest pain</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dizziness</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dizziness</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Fatigue</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Fatigue</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Headache</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Headache</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Micturition urgency</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Micturition urgency</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Nightmare</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Nightmare</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Panic attack</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Panic attack</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pollakiuria</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pollakiuria</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>GABAPENTIN</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>3</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>300 mg, TID</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<activesubstance>
					<activesubstancename>GABAPENTIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>WELLBUTRIN XL</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>300 mg, QD</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<activesubstance>
					<activesubstancename>BUPROPION HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>VENLAFAXINE XR</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>300 mg, BID</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<activesubstance>
					<activesubstancename>VENLAFAXINE XR</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>SYNTHROID</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<drugstructuredosagenumb>.062</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>0.062 mg, UNK</drugdosagetext>
				<actiondrug code="3">Dose Increased</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LEVOTHYROXINE SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>SYNTHROID</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<drugstructuredosagenumb>.088</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>0.088 mg, UNK</drugdosagetext>
				<actiondrug code="3">Dose Increased</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LEVOTHYROXINE SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>MINESTRIN</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>1 DF, QD</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<actiondrug code="5">Unknown</actiondrug>
				<activesubstance>
					<activesubstancename>ETHINYLESTRADIOL, NORETHISTERONE ACETATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>COLACE</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<drugstructuredosagenumb>.5</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>0.5 DF, QD</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<actiondrug code="5">Unknown</actiondrug>
				<activesubstance>
					<activesubstancename>DOCUSATE SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012CA082011, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from a <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>via patient oriented program <Semaphore x="619905" class="Medicine" value="Gilenya" score="1.00" ID="186396">Gilenya </Semaphore>Go marketing program on 19 Sep 2012 and follow up report received from the consumer (patient) via <Semaphore x="619905" class="Medicine" value="Gilenya" score="1.00" ID="186396">Gilenya </Semaphore>Go program on 20 Sep 2012 and follow up report received from the consumer (patient) via <Semaphore x="619905" class="Medicine" value="Gilenya" score="1.00" ID="186396">Gilenya </Semaphore>Go program on 08 Nov 2012 and follow up report received from the consumer (patient) via <Semaphore x="619905" class="Medicine" value="Gilenya" score="1.00" ID="186396">Gilenya </Semaphore>Go program on 09 Nov 2012 and follow up report received from the consumer (patient) via <Semaphore x="619905" class="Medicine" value="Gilenya" score="1.00" ID="186396">Gilenya </Semaphore>Go program on 18 Jan 2013: This report refers to a 51-year old female patient (ID: G120711-003). Patient was told around the same time that she started on <Semaphore x="619905" class="Medicine" value="Gilenya" score="1.00" ID="186396">Gilenya </Semaphore>that she <Semaphore x="1936750" class="Procedure" value="Findings-Based Question" score="0.68" ID="C91103">had <Semaphore x="1620679" class="Disease or Finding" value="Borderline Hypertension" score="1.00" ID="C3907">borderline hypertension </Semaphore></Semaphore>and was not on any medication. Patient also had a history of <Semaphore x="1534652" class="Disease or Finding" value="Anxiety Disorder" score="1.00" ID="C2878">anxiety </Semaphore>for which she was taking an unspecified medication. Concomitant medications included <Semaphore x="608883" class="Medicine" value="gabapentin" score="0.49" ID="251588">gabapentin</Semaphore>, <Semaphore x="1361983" class="Medicine" value="Wellbutrin" score="0.49" ID="268096">Wellbutrin </Semaphore>XL (<Semaphore x="251746" class="Medicine" value="buPROPion Hydrochloride" score="0.49" ID="241503">bupropion hydrochloride</Semaphore>), <Semaphore x="1324788" class="Medicine" value="venlafaxine" score="0.49" ID="266954">venlafaxine </Semaphore>XR, <Semaphore x="1243220" class="Medicine" value="Synthroid" score="0.74" ID="249232">Synthroid </Semaphore>(<Semaphore x="782363" class="Medicine" value="Levothyroxine Sodium" score="0.49" ID="266997">levothyroxine <Semaphore x="2536895" class="Procedure" value="Sodium Measurement" score="1.00" ID="C64809">sodium</Semaphore></Semaphore>) and Minestrin (ethinylestradiol, norethisterone <Semaphore x="32920" class="Medicine" value="Acetate" score="0.49" ID="239852">acetate</Semaphore>). This patient received <Semaphore x="619905" class="Medicine" value="Gilenya" score="1.00" ID="186396">Gilenya </Semaphore>(<Semaphore x="576745" class="Medicine" value="fingolimod hydrochloride" score="0.49" ID="186391">fingolimod hydrochloride</Semaphore>) (lot number: S0008, expiry date: Feb 2013) at a daily dose of 0.5 mg for <Semaphore x="3115890" class="MedDRA LLT" value="Multiple sclerosis relapse" score="1.00" ID="10048393"><Semaphore x="2451967" class="Disease or Finding" value="Recurrent Disease, Distant Site" score="1.00" ID="C55073">relapsing </Semaphore>remitting <Semaphore x="2245768" class="Disease or Finding" value="Multiple Sclerosis" score="1.00" ID="C3243">multiple sclerosis </Semaphore></Semaphore>(RRMS) on 18 Sep 2012. After starting the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>on the same day at 13:15, she developed increased <Semaphore x="2912073" class="MedDRA LLT" value="Dizziness" score="1.00" ID="10013573">lightheadedness </Semaphore>(worse than usual episodes which she was known to have <Semaphore x="2502875" class="Disease or Finding" value="Second-Degree Burn" score="1.00" ID="C76131">secondary </Semaphore>to <Semaphore x="2245768" class="Disease or Finding" value="Multiple Sclerosis" score="1.00" ID="C3243">multiple sclerosis</Semaphore>) and <Semaphore x="2815617" class="MedDRA LLT" value="Blood pressure increased" score="1.00" ID="10005750">increased blood pressure </Semaphore>of 148/98. <Semaphore x="1877067" class="Procedure" value="Electrocardiography" score="1.00" ID="C38053">Electrocardiogram </Semaphore>was done at 13: 29 that showed <Semaphore x="2319682" class="Disease or Finding" value="Normal Sinus Rhythm" score="1.00" ID="C102681">normal <Semaphore x="3248925" class="MedDRA LLT" value="Sinus rhythm" score="1.00" ID="10048815">sinus rhythm </Semaphore></Semaphore>and vital <Semaphore x="2521321" class="Disease or Finding" value="Sign" score="1.00" ID="C53458">signs </Semaphore>were normal. At 14:00, <Semaphore x="2912073" class="MedDRA LLT" value="Dizziness" score="1.00" ID="10013573">lightheadedness </Semaphore>decreased in intensity but was not <Semaphore x="1563494" class="AnatomicStructure" value="Back" score="1.00" ID="C13062">back </Semaphore>to usual baseline state. Her non <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>included elevated <Semaphore x="1944242" class="AnatomicStructure" value="Foot" score="1.00" ID="C32622">feet </Semaphore>and drinking <Semaphore x="1361751" class="Medicine" value="Water" score="0.49" ID="196879">water</Semaphore>. The patient's <Semaphore x="2912073" class="MedDRA LLT" value="Dizziness" score="1.00" ID="10013573">lightheadedness </Semaphore>was resolved within a few hours. The patient also reported having a bit of a <Semaphore x="2008813" class="Disease or Finding" value="Headache" score="1.00" ID="C34661">headache </Semaphore>in the evening, which subsided after taking a <Semaphore x="1309761" class="Medicine" value="Tylenol" score="0.49" ID="241273">Tylenol </Semaphore>(<Semaphore x="2737985" class="MedDRA LLT" value="Analgesic drug level" score="1.00" ID="10060090">paracetamol</Semaphore>). The patient <Semaphore x="1936750" class="Procedure" value="Findings-Based Question" score="0.68" ID="C91103">had a slight <Semaphore x="2008813" class="Disease or Finding" value="Headache" score="1.00" ID="C34661">headache </Semaphore></Semaphore>on 19 Sep 2012 and <Semaphore x="1928772" class="Procedure" value="Feel Tired" score="1.00" ID="C104301">felt tired</Semaphore>. She slept part of the day. On 20 Sep 2012, the patient felt <Semaphore x="1995141" class="AnatomicStructure" value="Greater Curvature of the Stomach" score="1.00" ID="C12262">great </Semaphore>and rested. During follow up on 08 Nov 2012, the patient reported that she consulted her <Semaphore x="2209876" class="Occupation" value="Medical Occupation" score="0.58" ID="C19254">physician </Semaphore>(exact date unknown) about her elevated <Semaphore x="2625183" class="Procedure" value="Thyrotropin Measurement" score="1.00" ID="C64813">thyroid stimulating <Semaphore x="2032177" class="Disease or Finding" value="Hormone-Resistant Breast Cancer" score="1.00" ID="C114932">hormone </Semaphore></Semaphore>(<Semaphore x="2625183" class="Procedure" value="Thyrotropin Measurement" score="1.00" ID="C64813">TSH</Semaphore>) <Semaphore x="779631" class="Medicine" value="Level" score="0.49" ID="187620">level </Semaphore>(7.26). She was on <Semaphore x="1243220" class="Medicine" value="Synthroid" score="0.74" ID="249232">Synthroid </Semaphore>medication for many years at the dose of 0.0625 mg and this time it was increased to 0.088 mg. Upon follow up on 09 Nov 2012, the patient stated that the <Semaphore x="1936750" class="Procedure" value="Findings-Based Question" score="0.68" ID="C91103"><Semaphore x="2008813" class="Disease or Finding" value="Headache" score="1.00" ID="C34661">headache </Semaphore>had </Semaphore>decreased but she had increased <Semaphore x="1926717" class="Disease or Finding" value="Fatigue" score="1.00" ID="C3036">fatigue</Semaphore>, since she got up a few times during the night to go to the bathroom. She had noticed in the past weeks that she was going to the washroom more often and had <Semaphore x="1602068" class="AnatomicStructure" value="Bladder Tissue" score="1.00" ID="C32209">bladder </Semaphore>urgency. She also reported that a few weeks (date unknown) ago she had two 30 seconds episodes of <Semaphore x="2553501" class="Disease or Finding" value="Stabbing Pain" score="1.00" ID="C101182">stabbing <Semaphore x="3167117" class="MedDRA LLT" value="Pain" score="1.00" ID="10033371">pain </Semaphore></Semaphore>in her mid chest. She saw the <Semaphore x="2209876" class="Occupation" value="Medical Occupation" score="0.58" ID="C19254">neurologist </Semaphore>the next day and had an <Semaphore x="2923526" class="MedDRA LLT" value="Electrocardiogram normal" score="1.00" ID="10014373"><Semaphore x="1877067" class="Procedure" value="Electrocardiography" score="1.00" ID="C38053">ECG </Semaphore>which was normal</Semaphore>. Upon follow up received on 18 Jan 2013, she reported that she <Semaphore x="2668417" class="AnatomicStructure" value="Upper-Inner Quadrant of the Breast" score="1.00" ID="C12301">woke </Semaphore>up with <Semaphore x="2854851" class="MedDRA LLT" value="Chest discomfort" score="1.00" ID="10008469">pressure in her <Semaphore x="1762050" class="AnatomicStructure" value="Chest" score="1.00" ID="C25389">chest </Semaphore></Semaphore>around 6: 45 am and stated that it was not in her <Semaphore x="2520062" class="AnatomicStructure" value="Shoulder" score="1.00" ID="C25203">shoulder </Semaphore>area or <Semaphore x="1543524" class="AnatomicStructure" value="Arm" score="1.00" ID="C32141">arm</Semaphore>. She also mentioned that she had a <Semaphore x="1534652" class="Disease or Finding" value="Anxiety Disorder" score="1.00" ID="C2878">panic attack </Semaphore>a few nights ago after a <Semaphore x="3143646" class="MedDRA LLT" value="Nightmare" score="1.00" ID="10029412">nightmare</Semaphore>. Over the last few days, she had stayed in <Semaphore x="1592300" class="Disease or Finding" value="Binge Eating Disorder" score="1.00" ID="C97162">bed </Semaphore>since she had increase <Semaphore x="1926717" class="Disease or Finding" value="Fatigue" score="1.00" ID="C3036">fatigue </Semaphore>and <Semaphore x="2765084" class="MedDRA LLT" value="Asthenia" score="1.00" ID="10003549">generalized <Semaphore x="2218009" class="Disease or Finding" value="Mental and Behavioral Signs and Symptoms" score="0.58" ID="C3858">weakness </Semaphore></Semaphore>that she has had in the past. She had an <Semaphore x="1877067" class="Procedure" value="Electrocardiography" score="1.00" ID="C38053">electrocardiogram </Semaphore>(<Semaphore x="1877067" class="Procedure" value="Electrocardiography" score="1.00" ID="C38053">ECG</Semaphore>) a few weeks ago and all was fine. She was advised to go to the emergency room (<Semaphore x="1887644" class="AnatomicStructure" value="Endoplasmic Reticulum" score="1.00" ID="C13230">ER</Semaphore>) to be looked at. Action taken with <Semaphore x="619905" class="Medicine" value="Gilenya" score="1.00" ID="186396">Gilenya </Semaphore>was unknown. Event <Semaphore x="2912073" class="MedDRA LLT" value="Dizziness" score="1.00" ID="10013573">lightheadedness </Semaphore>was reported as medically significant. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the events <Semaphore x="2912073" class="MedDRA LLT" value="Dizziness" score="1.00" ID="10013573">lightheadedness </Semaphore>and <Semaphore x="2008813" class="Disease or Finding" value="Headache" score="1.00" ID="C34661">headache </Semaphore>was reported as completely resolved and was not reported for other events. No information was provided about causality <Semaphore x="2397639" class="Procedure" value="Physical Examination" score="1.00" ID="C20989">assessment</Semaphore>.Follow up report received from the consumer (patient) via <Semaphore x="619905" class="Medicine" value="Gilenya" score="1.00" ID="186396">Gilenya </Semaphore>Go program on 20 Sep 2012. New events (<Semaphore x="1926717" class="Disease or Finding" value="Fatigue" score="1.00" ID="C3036">fatigue </Semaphore>and <Semaphore x="2008813" class="Disease or Finding" value="Headache" score="1.00" ID="C34661">headache</Semaphore>), <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of the event <Semaphore x="2008813" class="Disease or Finding" value="Headache" score="1.00" ID="C34661">headache </Semaphore>and <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event <Semaphore x="1861243" class="Disease or Finding" value="Dizziness" score="1.00" ID="C37943">dizziness </Semaphore>were updated.Follow up report received from the consumer (patient) via <Semaphore x="619905" class="Medicine" value="Gilenya" score="1.00" ID="186396">Gilenya </Semaphore>Go program on 08 Nov 2012: New event (<Semaphore x="2625183" class="Procedure" value="Thyrotropin Measurement" score="1.00" ID="C64813">TSH </Semaphore>levels were elevated at 7.26) and concomitant medication dose were updated.Follow up report received from the consumer (patient) via <Semaphore x="619905" class="Medicine" value="Gilenya" score="1.00" ID="186396">Gilenya </Semaphore>Go program on 09 Nov 2012: Information related to new events (<Semaphore x="2671728" class="Disease or Finding" value="Urinary Frequency" score="1.00" ID="C26906"><Semaphore x="3110049" class="MedDRA LLT" value="Micturition urgency" score="1.00" ID="10027566"><Semaphore x="2672701" class="Disease or Finding" value="Urinary Urgency" score="1.00" ID="C50792">urinary <Semaphore x="2672701" class="Disease or Finding" value="Urinary Urgency" score="1.00" ID="C50792">urgency</Semaphore><Semaphore x="2671728" class="Disease or Finding" value="Urinary Frequency" score="1.00" ID="C26906">, <Semaphore x="2671728" class="Disease or Finding" value="Urinary Frequency" score="1.00" ID="C26906">urinary </Semaphore></Semaphore></Semaphore>
       <Semaphore x="2671728" class="Disease or Finding" value="Urinary Frequency" score="1.00" ID="C26906">
        <Semaphore x="3194400" class="MedDRA LLT" value="Pollakiuria" score="1.00" ID="10036018">
         </Semaphore></Semaphore></Semaphore>
      <Semaphore x="2671728" class="Disease or Finding" value="Urinary Frequency" score="1.00" ID="C26906">
       <Semaphore x="3194400" class="MedDRA LLT" value="Pollakiuria" score="1.00" ID="10036018">
        <Semaphore x="2671728" class="Disease or Finding" value="Urinary Frequency" score="1.00" ID="C26906">frequency </Semaphore></Semaphore></Semaphore></Semaphore>and <Semaphore x="1761238" class="Disease or Finding" value="Chest Pain" score="1.00" ID="C38665">chest pain</Semaphore>) was updated.Follow up report received from the consumer (patient) via <Semaphore x="619905" class="Medicine" value="Gilenya" score="1.00" ID="186396">Gilenya </Semaphore>Go program on 18 Jan 2013: Information related to patient's <Semaphore x="1875899" class="Disease or Finding" value="Electrical Exposure" score="1.00" ID="C45407">current </Semaphore>conditions (<Semaphore x="1620679" class="Disease or Finding" value="Borderline Hypertension" score="1.00" ID="C3907">borderline hypertension</Semaphore>, <Semaphore x="1534652" class="Disease or Finding" value="Anxiety Disorder" score="1.00" ID="C2878">anxiety</Semaphore>), new events (<Semaphore x="2854851" class="MedDRA LLT" value="Chest discomfort" score="1.00" ID="10008469"><Semaphore x="1762050" class="AnatomicStructure" value="Chest" score="1.00" ID="C25389">chest </Semaphore>pressure</Semaphore>, <Semaphore x="1534652" class="Disease or Finding" value="Anxiety Disorder" score="1.00" ID="C2878">panic attack</Semaphore>, <Semaphore x="3143646" class="MedDRA LLT" value="Nightmare" score="1.00" ID="10029412">nightmare </Semaphore>and <Semaphore x="2765084" class="MedDRA LLT" value="Asthenia" score="1.00" ID="10003549">generalized <Semaphore x="2218009" class="Disease or Finding" value="Mental and Behavioral Signs and Symptoms" score="0.58" ID="C3858">weakness</Semaphore></Semaphore>) and medical narrative (she had an <Semaphore x="1877067" class="Procedure" value="Electrocardiography" score="1.00" ID="C38053">ECG </Semaphore>a few weeks ago and all was fine) was updated.</narrativeincludeclinical>
				<sendercomment>Medic Comment: The available reported data does not allow for a proper causality assessment. The case has been conservatively assessed as suspected and will be reassessed after the availability of follow up</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>